Tyra Bioscience Holds 2025 Annual Stockholders Meeting

Tyra Bioscience ( (TYRA) ) just unveiled an update.

On May 29, 2025, Tyra Biosciences held its 2025 Annual Meeting of Stockholders, where three directors were elected to serve three-year terms, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (TYRA) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Tyra Bioscience stock, see the TYRA Stock Forecast page.

Spark’s Take on TYRA Stock

According to Spark, TipRanks’ AI Analyst, TYRA is a Neutral.

Tyra Bioscience’s overall stock score reflects its high-risk profile typical for early-stage biotechnology firms. While the company demonstrates strong liquidity, its lack of revenue and increasing operational losses highlight financial challenges. Technical indicators show positive momentum, but the high valuation risk due to negative earnings limits the score. Investors should be cautious, considering both the potential for significant growth and the inherent risks.

To see Spark’s full report on TYRA stock, click here.

More about Tyra Bioscience

Tyra Biosciences, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment.

Average Trading Volume: 328,326

Technical Sentiment Signal: Sell

Current Market Cap: $469M

See more insights into TYRA stock on TipRanks’ Stock Analysis page.